X0306 4 2021-02-10 0 0001811063 Nuvation Bio Inc. NUVB 0001641354 Omega Fund V, L.P. 888 BOYLSTON ST., STE. 1111 BOSTON MA 02199 0 0 1 0 0001641355 Omega Fund V GP, L.P. 888 BOYLSTON ST., STE. 1111 BOSTON MA 02199 0 0 1 0 0001641348 Omega Fund V GP Manager, Ltd. 888 BOYLSTON ST., STE. 1111 BOSTON MA 02199 0 0 1 0 0001361712 Stampacchia Otello C/O OMEGA FUND V, LP 888 BOYLSTON ST., STE. 1111 BOSTON MA 02199 0 0 1 0 0001722050 Nessi Claudio C/O OMEGA FUND V, LP 888 BOYLSTON ST., STE. 1111 BOSTON MA 02199 0 0 1 0 0001652863 Paster Anne-Mari C/O OMEGA FUND V, LP 888 BOYLSTON ST., STE. 1111 BOSTON MA 02199 0 0 1 0 0001832320 DOIG MICHELLE C/O OMEGA FUND V, L.P. 888 BOYLSTON ST., STE. 1111 BOSTON MA 02199 1 0 0 0 Class A Common Stock 2021-02-10 4 C 0 8130097 A 27712373 D Class A Common Stock 2021-02-10 4 A 0 500000 10.00 A 28212373 D Series A Preferred Stock 2021-02-10 4 C 0 8130097 0.00 D Class A Common Stock 8130097 0 D Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). The transactions contemplated by the Merger Agreement are referred to herein as the "Business Combination." Includes 19,582,276 shares issued in connection with the conversion of shares of Class A Common Stock in the Business Combination, as defined herein. The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Michelle Doig is a partner of Omega V and shares voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager, the Omega Directors and Michelle Doig disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. On October 20, 2020, the Issuer entered into subscription agreements (the "Subscription Agreements") with certain investors (the "PIPE Investors") pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, as defined herein, an aggregate of $476,550,000 of the Issuer's shares of Class A Common Stock at a price of $10.00 per share, or an aggregate of 47,655,000 shares of Class A Common Stock. The Reporting Person is among the PIPE Investors. Each share of Series A Preferred Stock stock automatically converted into Class A Common Stock on a 1-for-1 basis immediately prior to the closing of the Business Combination and has no expiration date nor conversion price. /s/ Ron A. Metzger, as an authorized signatory for each Reporting Person. 2021-02-12